Life Sciences

  • November 10, 2025

    Law360 MVP Awards Go To Top Attorneys From 76 Firms

    The attorneys chosen as Law360's 2025 MVPs have distinguished themselves from their peers by securing significant achievements in high-stakes litigation, complex global matters and record-breaking deals.

  • November 10, 2025

    GTCR's $627M Medical Coatings Acquisition Can Get Moving

    GTCR BC Holdings LLC can continue with its plan to acquire the nation's leading medical coatings supplier and merge it with the nation's second leading provider while federal regulators challenge the transaction in-house, an Illinois federal judge said Monday, refusing to halt the deal.

  • November 10, 2025

    IRhythm Denied Early Win On Investor Scienter & Loss Claims

    Heart monitor maker iRhythm Technologies cannot get an early win in a proposed investor class action alleging it made misleading disclosures about one of its devices, a San Francisco federal judge has determined.

  • November 10, 2025

    Pfizer Again Asks Judge To Toss States' Price-Fixing Case

    Pfizer has again asked a Connecticut federal judge to throw out claims it faces in a sprawling dermatology drug price-fixing lawsuit filed by multiple states against several pharmaceutical companies, arguing allegations against it were "scant and cursory."

  • November 10, 2025

    Medtech Co-Founder Tells Chancery Father-Son Cut Him Out

    A co-founder of a medtech company has sued in the Delaware Chancery Court alleging the two other co-founders, who are father and son, of engineering a covert squeeze-out aimed at stripping him of his 30% ownership stake just as the company approached a potentially lucrative fundraiser.

  • November 10, 2025

    Novartis Argues For High Court To Skip Entresto Patent Case

    Novartis Pharmaceuticals Corp. is urging the U.S. Supreme Court to skip MSN Pharmaceuticals Inc.'s request for review of a Federal Circuit decision that barred MSN's generic version of Novartis' blockbuster cardiovascular drug Entresto, asserting there is no conflict in the circuit for the justices to look at.

  • November 10, 2025

    FDA Lifts Hormone Replacement 'Black Box' Warnings

    The U.S. Food and Drug Administration on Monday said it was removing the "black box" warnings from hormone replacement therapy treatments for menopause for the risks of cardiovascular disease, breast cancer and probable dementia.

  • November 10, 2025

    FTC Risks Help Push Metsera Back To Pfizer

    Novo Nordisk AS' aspirations to pry Metsera away from Pfizer Inc. collapsed over the weekend under the pressure of a revised Pfizer offer, twin court challenges and "a call from the U.S. Federal Trade Commission."

  • November 10, 2025

    Chancery Drops Claims In Murder-Linked Bio Co. Merger Fight

    The Delaware Chancery Court dismissed a biotech company's claims against the husband and investment vehicle of convicted fraudster Serhat Gumrukcu, whose murder-for-hire plot allegedly helped conceal past misconduct ahead of a 2018 merger.

  • November 10, 2025

    Catching Up With Delaware's Chancery Court

    Delaware's top court issued a flurry of rulings last week and heard arguments on recently passed legislation that expanded liability shields for some corporate acts while the Court of Chancery passed on another round of arguments over control of Caribbean broadcaster Caribevision.

  • November 07, 2025

    4th Circ. Opioid Case Brings Public Nuisance Back To The Fore

    The Fourth Circuit's ruling that upturned a lower court win for drug distributors in a battle with the West Virginia county at the epicenter of the opioid epidemic was a blast from the past from the fever pitch of courtroom battles over the national crisis just a few years ago.

  • November 07, 2025

    States Say Macquarie Not Applicable To NH High Court Case

    State securities regulators are urging New Hampshire's Supreme Court to uphold a fine against a medical device company whose leader was alleged to have misled investors about his prior legal issues, arguing that the case bears no resemblance to one ruled on by the U.S. Supreme Court last year.

  • November 07, 2025

    Sleep Apnea Device Co. Investor Says Rollout Was Botched

    Medical device company Inspire Medical Systems has been hit with a proposed investor class action alleging its shares dropped by nearly a third of their value after the public learned it concealed low demand and rollout shortcomings associated with its newest sleep apnea device.

  • November 07, 2025

    Spurned Pfizer Turns To Antitrust Law To Reclaim Biotech

    What may be a first-of-its-kind lawsuit is playing out as Pfizer Inc. turns to antitrust law to keep Novo Nordisk from usurping its bid for Metsera.

  • November 07, 2025

    Canadian Co. Blocked From Using 'Deep Cleansing Oil' Brand

    A Pennsylvania federal judge has permanently blocked a Canadian skincare company from infringing a competitor's trademark for "Deep Cleansing Oil," after it failed to respond to the case.

  • November 07, 2025

    Seattle Pot Shop Slapped With Site Tracking Pixel Privacy Suit

    A Seattle cannabis dispensary has been hit with a proposed class action in Washington federal court by a customer who claims the retailer shared his private information about medical marijuana appointments and pot purchases with Google and other third parties by using online browser tracking tools on its website.

  • November 07, 2025

    USPTO Extends Deadline For PTAB Institution Rules Feedback

    The U.S. Patent and Trademark Office has provided a 15-day extension for giving feedback on proposed rules that will likely reduce the institution of certain patent challenges at the Patent Trial and Appeal Board, with Director John Squires saying "now's the time" to finalize rulemaking on discretionary denial issues.

  • November 07, 2025

    Jury Clears Novo Nordisk Of Medicaid Fraud Over Blood Drug

    A Tacoma federal jury cleared Novo Nordisk on Friday of allegations that it defrauded Washington state's Medicaid and Medicare systems by paying kickbacks and promoting off-label use to illegally boost prescriptions of its hemophilia drug NovoSeven.

  • November 07, 2025

    Fla. Judge Sentences HIV Drug Fraudster To 8 Years In Prison

    A Florida federal judge on Friday sentenced a man to more than eight years in prison after he pled guilty to a wire fraud-related charge in connection to a roughly $100 million HIV medication fraud scheme, referencing the harm that called into question the nation's pharmaceutical drug supply. 

  • November 07, 2025

    Merck Wins PTAB Fight Over Blockbuster Drug, Again

    Another cancer treatment patent owned by Johns Hopkins University and challenged by a Merck & Co. Inc. subsidiary didn't pass muster with the Patent Trial and Appeal Board, which on Thursday invalidated seven claims in the patent that's at issue in a disagreement between the parties.

  • November 07, 2025

    Taxation With Representation: Kirkland, Cravath, Paul Weiss

    In this week's Taxation With Representation, consumer products giant Kimberly-Clark acquires Tylenol maker Kenvue, shale producers SM Energy and Civitas Resources announce a merger, and power management company Eaton buys Boyd Corp.'s thermal business.

  • November 07, 2025

    Laborie Buys Postpartum Bleeding Device For Up To $465M

    Medical technology company Laborie Medical Technologies, advised by Simpson Thacher & Bartlett LLP and Cooley LLP, unveiled plans Friday to acquire a postpartum uterine bleeding device from New Jersey-based healthcare company Organon for up to $465 million.

  • November 06, 2025

    Pair Of Health-Focused Startups Net $423M In Combined IPOs

    Two startups, spanning the diagnostics and biotechnology sectors, began trading on Thursday after raising a combined $423 million in initial public offerings, guided by three law firms, as more companies continue going public despite a historic government shutdown that has reduced staffing at the U.S. Securities and Exchange Commission.

  • November 06, 2025

    'Send A Message' To Novo Nordisk Over Kickbacks, Jury Told

    Counsel for a whistleblower claiming Novo Nordisk paid illegal kickbacks to boost off-label prescribing of its hemophilia drug NovoSeven urged jurors during closing arguments Thursday to "send a message" to the drugmaker, saying it defrauded Washington state's Medicaid and Medicare systems out of nearly $100 million.

  • November 06, 2025

    CareFirst Urges Ban On J&J Character Talk At Stelara Trial

    Health insurer CareFirst is asking a Virginia federal judge to bar Johnson & Johnson from promoting its "good character" to a jury that will weigh class claims of anticompetitive conduct and patent fraud to extend market protection on the blockbuster autoimmune drug Stelara.

Expert Analysis

  • USPTO Under Squires: A Look At The First Month

    Author Photo

    New U.S. Patent and Trademark Office Director John Squires' opening acts — substantive and symbolic — signal a posture that is more welcoming to technological improvements and focused on rebalancing the office's gatekeeping role, say attorneys at Seyfarth.

  • Opinion

    Expert Reports Can't Replace Facts In Securities Fraud Cases

    Author Photo

    The Ninth Circuit's 2023 decision in Nvidia v. Ohman Fonder — and the U.S. Supreme Court's punt on the case in 2024 — could invite the meritless securities litigation the Private Securities Litigation Reform Act was designed to prevent by substituting expert opinions for facts to substantiate complaint assertions, say attorneys at A&O Shearman.

  • Opinion

    High Court, Not A Single Justice, Should Decide On Recusal

    Author Photo

    As public trust in the U.S. Supreme Court continues to decline, the court should adopt a collegial framework in which all justices decide questions of recusal together — a reform that respects both judicial independence and due process for litigants, say Michael Broyde at Emory University and Hayden Hall at the U.S. Bankruptcy Court for the District of Delaware.

  • Series

    Traveling Solo Makes Me A Better Lawyer

    Author Photo

    Traveling by myself has taught me to assess risk, understand tone and stay calm in high-pressure situations, which are not only useful life skills, but the foundation of how I support my clients, says Lacey Gutierrez at Group Five Legal.

  • Latest PTAB Moves Suggest A Subtle Recalibration

    Author Photo

    Recent decisions from the Patent Trial and Appeal Board, as U.S. Patent and Trademark Office Director John Squires transitions into his new role, offer new procedural and substantive tools for patent owners in procuring patent rights and enforcing them against would-be petitioners, say attorneys at Morgan Lewis.

  • Opinion

    DOJ's Tracing Rule For Pandemic Loan Fraud Is Untenable

    Author Photo

    In conducting investigations related to COVID-19 relief fraud, the government's assertion that loan proceeds are nonfungible and had to have been segregated from other funds is unsupported by underlying legislation, precedent or the language establishing similar federal relief programs, say Sharon McCarthy, Jay Nanavati and Lasya Ravulapati at Kostelanetz.

  • Del. Ruling Reaffirms High Bar To Plead Minority Control

    Author Photo

    The Delaware Court of Chancery's recent decision in Witmer v. Armistice maintains Delaware's strict approach to control and provides increased predictability for minority investors in their investment and corporate governance decisions, says Elena Davis at Ropes & Gray.

  • Series

    Law School's Missed Lessons: Client Service

    Author Photo

    Law school teaches you how to interpret the law, but it doesn't teach you some of the key ways to keeping clients satisfied, lessons that I've learned in the most unexpected of places: a book on how to be a butler, says Gregory Ramos at Armstrong Teasdale.

  • How Occasional Activists Have Reshaped Proxy Fights

    Author Photo

    The sophistication and breadth of first-time activist engagement continue to shape corporate governance and strategic outcomes, as evidenced across corporate annual meetings this summer, meaning advisers should anticipate continued innovation in tactics, increased regulatory complexity, and a persistent focus on board accountability, say attorneys at MoFo.

  • What To Expect After FDA Warnings To GLP-1 Compounders

    Author Photo

    The U.S. Food and Drug Administration's recent warning letters to companies advertising compounded versions of GLP-1 medications raise questions not just about the enforcement outlook for marketing such products, but also about the future of drug compounding as a whole, say attorneys at Spencer Fane.

  • Where 4th And 9th Circ. Diverge On Trade Secret Timing

    Author Photo

    Recent Fourth and Ninth Circuit decisions have revealed a deepening circuit split over when plaintiffs must specifically define their alleged trade secrets, turning the early stages of trade secret litigation into a key battleground and elevating the importance of forum selection, say attorneys at Skadden.

  • Series

    Adapting To Private Practice: 3 Tips On Finding The Right Job

    Author Photo

    After 23 years as a state and federal prosecutor, when I contemplated moving to a law firm, practicing solo or going in-house, I found there's a critical first step — deep self-reflection on what you truly want to do and where your strengths lie, says Rachael Jones at McKool Smith.

  • Series

    Painting Makes Me A Better Lawyer

    Author Photo

    Painting trains me to see both the fine detail and the whole composition at once, enabling me to identify friction points while keeping sight of a client's bigger vision, but the most significant lesson I've brought to my legal work has been the value of originality, says Jana Gouchev at Gouchev Law.

  • Courts Are Still Grappling With McDonnell, 9 Years Later

    Author Photo

    The Seventh and D.C. Circuits’ recent decisions in U.S. v. Weiss and U.S. v. Paitsel, respectively, demonstrate that courts are still struggling to apply the U.S. Supreme Court’s 2016 ruling in McDonnell v. U.S., which narrowed the scope of “official acts” in federal bribery cases, say attorneys at Quinn Emanuel.

  • AI Will Transform Patent Examination For The Better

    Author Photo

    The U.S. Patent and Trademark Office's increasing use of artificial intelligence tools will result in patents that are more thoroughly vetted, and patent applicants and practitioners will need to adapt their drafting strategies and address stronger and more sophisticated rejections, say attorneys at Troutman.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.